-
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Friday, June 29, 2012 - 6:36am | 157Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "...
-
Lexicon Pharmaceuticals Soaring After Stifel Nicolaus Raises Price Target
Tuesday, June 26, 2012 - 12:30pm | 132Lexicon Pharmaceuticals (NASDAQ: LXRX) is trading higher on the session after Stifel Nicolaus raised its price target from $3 to $4 and reiterated the Buy rating. On Monday, the company announced positive phase 2 trial results for its diabetes drug. Stifel Nicolaus stated, "Management intends to...
-
UPDATE: Stifel Nicolaus Raises PT to $4 on Lexicon Pharmaceuticals on LX4211 P2b Efficacy Data
Tuesday, June 26, 2012 - 9:00am | 110Stifel Nicolaus reiterates its Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a price target that is raised from $3 to $4. Stifel Nicolaus notes, "Management intends to move the once-daily (QD) 400mg dose forward into P3 development – a decision we fully support given the meaningfully...
-
Benzinga's Top Pre-Market Gainers
Monday, June 25, 2012 - 8:09am | 125Lexicon Pharmaceuticals (NASDAQ: LXRX) surged 21.99% to $2.33 in the pre-market session. Lexicon Pharmaceuticals reported positive results of LX4211 Phase 2b trial for type 2 diabetes. Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) added 6.87% to $40.62 in the pre-market session. Teva...
-
Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
Monday, June 25, 2012 - 6:55am | 160Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that LX4211, an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), showed substantial, dose-dependent, statistically-significant reductions in hemoglobin A1c (HbA1c) in a Phase 2b trial in...
-
Ligand Announces Positive Preclinical Data on LGD-6972 at the American Diabetes Association's 72nd Scientific Sessions
Monday, June 11, 2012 - 8:03am | 89Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that a poster entitled “LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes” was presented at the 72nd Scientific Sessions of the American Diabetes Association (...
-
Today's Top Small-Cap Winners!
Tuesday, June 5, 2012 - 6:17pm | 421A total of nine small-cap stocks recorded gains of great than 15% on Tuesday. All of these companies have market caps of between $50 and $300 million. Below, Benzinga highlights the movements in these stocks. Amyris, Inc. (NASDAQ: AMRS) - This stock jumped more than 27% on Tuesday and closed the...
-
Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis
Tuesday, June 5, 2012 - 8:01am | 59Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone...
-
Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure; Drug Generally Well Tolerated
Thursday, May 17, 2012 - 4:06pm | 267Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the...
-
Maxygen to Receive $30M Payment from Bayer
Monday, May 14, 2012 - 9:06am | 127Maxygen, Inc. (Nasdaq: MAXY) today announced that it will receive a $30.0 million payment from Bayer HealthCare LLC in connection with Bayer's continued clinical development of a recombinant factor VIIa product candidate for the treatment of hemophilia. Maxygen sold the recombinant factor VIIa...
-
Maxygen to Receive $30 Million Payment from Bayer
Monday, May 14, 2012 - 9:02am | 127Maxygen, Inc. (Nasdaq: MAXY) today announced that it will receive a $30.0 million payment from Bayer HealthCare LLC in connection with Bayer's continued clinical development of a recombinant factor VIIa product candidate for the treatment of hemophilia. Maxygen sold the recombinant factor VIIa...
-
Luna Innovations Signs Development Agreement with Philips Medical
Tuesday, May 8, 2012 - 9:00am | 92Luna Innovations Incorporated (NASDAQ: LUNA), a leading developer of fiber-optic sensing technology, today announced a development agreement with Philips Healthcare, to conduct work in advancing Luna's technology towards the commercialization of fiber-optic shape sensing in the non-robotic medical...
-
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Thursday, May 3, 2012 - 7:03am | 143Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes. LX4211, a dual inhibitor of sodium glucose transporter 1 and 2 (SGLT1 and SGLT2), was designed to...
-
Metabolix Awarded Two U.S. Patents for Technology to Produce Biobased Polymers and Industrial Chemicals
Wednesday, April 25, 2012 - 9:01am | 130Metabolix, Inc. (NASDAQ: MBLX) today announced that the company has been awarded two new patents from the U.S. Patent and Trademark Office (PTO) related to the novel and efficient production of biobased polymers and industrial chemicals. U.S. Patent 8,093,022 titled “Polyhydroxalkanoate...
-
Luna Innovations and Intuitive Surgical Extend Relationship
Wednesday, March 28, 2012 - 9:45am | 62Luna Innovations Incorporated (NASDAQ: LUNA) announced today that it will be extending its development work through 2012 under its development and supply agreement with Intuitive Surgical, Inc. (NASDAQ: ISRG), as they work towards the integration of Luna's shape and position sensing technology into...